We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$644M
AUM Growth
+$56M
Cap. Flow
+$39.2M
Cap. Flow %
6.09%
Top 10 Hldgs %
67.17%
Holding
35
New
5
Increased
14
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$27M
2
FBRX icon
Forte Biosciences
FBRX
+$19.2M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$16M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$11M
5
LOXO
Loxo Oncology, Inc
LOXO
+$7.94M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$31.6M
2
BPMC
Blueprint Medicines
BPMC
+$21.7M
3
IMDZ
Immune Design Corp.
IMDZ
+$8.39M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$7.07M
5
FATE icon
Fate Therapeutics
FATE
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 78.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$80.6M 12.52%
1,591,646
-510,634
-24% -$21.7M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$77.2M 11.99%
8,248,416
+257,844
+3% +$1.89M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$50.7M 7.88%
6,059,625
+3,296,539
+119% +$27M
ANAB icon
4
AnaptysBio
ANAB
$1.63B
$39.7M 6.17%
1,659,200
-79,400
-5% -$2M
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
$37.2M 5.77%
463,386
+143,386
+45% +$7.94M
CBIO
6
Crescent Biopharma
CBIO
$555M
$33.1M 5.15%
29,702
+1,439
+5% +$1.19M
CTMX icon
7
CytomX Therapeutics
CTMX
$714M
$31.4M 4.88%
2,026,998
+222,323
+12% +$3.35M
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$28.5M 4.42%
8,596,357
+4,116,666
+92% +$16M
FWP
9
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$28.2M 4.38%
198,265
– –
CNCE
10
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$25.9M 4.02%
1,856,895
-479,714
-21% -$7.07M
CYTK icon
11
Cytokinetics
CYTK
$10.9B
$24.1M 3.74%
1,990,321
-2,270,515
-53% -$31.6M
PVLA
12
Palvella Therapeutics
PVLA
$2.15B
$17.7M 2.74%
43,649
+19,686
+82% +$5.75M
ACHN
13
DELISTED
Achillion Pharmaceuticals
ACHN
$16M 2.49%
3,490,077
+204,677
+6% +$823K
FBRX icon
14
Forte Biosciences
FBRX
$1.58B
$15.4M 2.39%
+3,411
New +$19.2M
BLRX
15
BioLineRX
BLRX
$11.7M
$14.9M 2.31%
29,167
– –
OMED
16
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$14.7M 2.28%
4,400,289
+2,639,800
+150% +$11M
INFI
17
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$12.3M 1.92%
7,866,108
– –
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
$11.6M 1.81%
3,133,224
– –
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.2B
$11.1M 1.72%
3,518,830
+569,036
+19% +$2.22M
XOMA
20
DELISTED
Xoma
XOMA
$10.5M 1.63%
1,502,800
– –
ARQL
21
DELISTED
Arqule Inc
ARQL
$9.18M 1.42%
7,400,128
– –
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$8.33M 1.29%
+153,846
New +$7.13M
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
$7.25M 1.13%
+700,000
New +$5.68M
ALPN
24
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.37M 0.99%
661,202
+195,083
+42% +$1.87M
ONCT
25
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.86M 0.91%
7,917
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2017 Portfolio in Review

As of Q2 2017, BVF Inc held 35 positions worth $644M, up 9.5% from $588M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

BVF Inc deployed $39.2M of net new capital in Q2 2017, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Forte Biosciences: 3,411 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $31.6M trimmed.

  • BVF Inc's largest Q2 2017 buy was Forte Biosciences: 3,411 shares worth $15.4M.
  • BVF Inc added most to Array Biopharma Inc in Q2 2017, an estimated $27M increase.
  • BVF Inc's biggest Q2 2017 reduction was Cytokinetics, cutting an estimated $31.6M.
  • BVF Inc fully exited Immune Design Corp. in Q2 2017, selling an estimated $8.39M.
  • BVF Inc's ten largest holdings make up 67% of its $644M portfolio in Q2 2017.
  • BVF Inc opened 5 new positions and closed 1 in Q2 2017.
  • BVF Inc's portfolio value rose 9.5% quarter-over-quarter to $644M.

Based on BVF Inc's 13F filing for Q2 2017, filed 14 Aug 2017.